Grifols launches Xembify in USA

Spanish plasma-derived medicines company Grifols (GRF: MC) today announced the launch of its latest immunoglobulin (IG) innovation, Xembify (immune globulin subcutaneous human-klhw), the company’s first 20% subcutaneous immunoglobulin therapy for the treatment of patients aged two years and older with primary immunodeficiency (PI).

With proven safety, efficacy, and tolerability, Xembify offers subcutaneous administration to patients in the treatment of PI, which are rare and chronic genetic disorders that occur in people born with an impaired or absent immune system. There are roughly 150,000 patients with PI who may be appropriate for IG therapy.

Strengthening Grifols’ growing IG portfolio for PI treatment, Xembify features a balanced formulation for the treatment of a wide range of PI patients, inclusive of those with risk factors, such as diabetes or cardiac impairment. Xembify was approved by the US Food and Drug Administration (FDA) in July 2019.